Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 727 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, and KEYNOTE-991 May 20, 2021 HTAN: Mapping Tumors across Space and Time Using Cutting-Edge Technologies February 12, 2019 Life-saving scheme to improve cancer screening among Muslim women July 20, 2023 Workout Wednesday – Back Stretches Part 2 July 29, 2020 Load more HOT NEWS 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung... 2020 National Cancer Opinion Survey: Cancer Screening and Mental Health During... Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows 15% of People With Lung Cancer Have an Inherited Mutation for...
